ABCL575 for Healthy Subjects
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment called ABCL575 to evaluate its safety and tolerability. Participants will receive either a single dose of ABCL575 or a placebo (a harmless, inactive substance) through a small injection under the skin. The trial seeks healthy individuals who do not smoke or have major health issues. As an Early Phase 1 trial, this research aims to understand how ABCL575 works in people, offering participants the opportunity to be among the first to receive this new treatment.
Do I have to stop taking my current medications for the trial?
Yes, you will need to stop taking any prescription drugs (except for hormonal contraceptives or hormone replacement therapy) 28 days before the study drug is given, and any over-the-counter products 7 days before.
Is there any evidence suggesting that ABCL575 is likely to be safe for humans?
Research has shown that ABCL575 was safe in early animal tests. Animals tolerated doses up to 100 mg/kg, the highest amount tested. Researchers administered the drug intravenously and subcutaneously. Importantly, these tests reported no negative effects. In this early-phase trial, researchers focus primarily on assessing the drug's safety and tolerability in humans. While earlier studies appear promising, this trial marks one of the initial steps in human testing of ABCL575, making it crucial to stay updated on new findings.12345
Why do researchers think this study treatment might be promising?
ABCL575 is unique because it is administered via a subcutaneous injection, which can be more convenient and less invasive than other forms of drug delivery like oral tablets or intravenous infusions. This treatment stands out because it offers a different mechanism of action, potentially providing benefits that current treatments for various conditions may not offer. Researchers are excited about ABCL575 because it could lead to faster or more effective results with fewer side effects, giving patients a better quality of life.
What evidence suggests that ABCL575 could be effective?
Research has shown that ABCL575 could be a promising treatment due to its mechanism of action. In early lab studies, ABCL575, an antibody, demonstrated strong potential by blocking pathways that cause inflammation. This suggests it might help reduce inflammation in conditions like atopic dermatitis, which leads to itchy, inflamed skin. Although these findings come from early lab studies, they indicate that ABCL575 might effectively treat inflammation-related issues. However, more research is needed to confirm its effectiveness in people. In this trial, healthy participants will receive a single dose of ABCL575 or a placebo to further investigate its potential effects.24678
Who Is on the Research Team?
Eric Sicard
Principal Investigator
Altasciences Company Inc.
Are You a Good Fit for This Trial?
This trial is for healthy individuals who want to participate in a study testing the safety of a new medication called ABCL575. Specific eligibility criteria are not provided, but typically participants must meet certain health standards and cannot have conditions that would exclude them from safely participating.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a single ascending dose of ABCL575 or placebo administered by subcutaneous injection
Follow-up
Participants are monitored for safety and tolerability after receiving the dose
What Are the Treatments Tested in This Trial?
Interventions
- ABCL575
Find a Clinic Near You
Who Is Running the Clinical Trial?
AbCellera Biologics Inc.
Lead Sponsor